Hematology/Oncology

Top Story

FDA grants priority review to MCNA for nonmuscle-invasive bladder cancer

August 31, 2015

The FDA granted priority review to MCNA for patients with high-risk nonmuscle-invasive bladder cancer, according to a press release from the drug’s manufacturer.

MCNA (mycobacterium phlei cell wall-nucleic acid complex, Telesta Therapeutics) — a biologic therapy derived from the cell wall fractionation of non-pathogenic bacteria —  is intended for patients with bladder cancer who are refractory to or who relapsed on front-line therapy with a therapeutic alternative to surgery.

David M. Gershenson, MD In the Journals

Younger age predicts worse survival from low-grade serous carcinoma of ovary, peritoneum

August 31, 2015
Women aged 35 or younger with low-grade serous carcinoma of the ovary or the peritoneum, as well as those with persistent disease upon therapy completion, have worse…
Mikkael A. Sekeres In the Journals

ED interventions reduce time to treatment of febrile neutropenia

August 31, 2015
The implementation of an intervention pathway reduced the time to administration of necessary antibiotics in the emergency department among adult patients with cancer…
In the Journals

Readmission rates may skew hospital quality measurements

August 31, 2015
Readmission rates were an ineffective measure of a hospital’s quality because they did not take into account readmissions from different hospitals, resulting in a…
NYU Langone appoints neuro-oncology chief

NYU Langone appoints neuro-oncology chief

August 30, 2015
Andrew S. Chi, MD, PhD, has been appointed chief of neuro-oncology at NYU Langone Medical Center’s Laura and Isaac Perlmutter Cancer Center.Chi, a…
More News Headlines »
CME
Hematology Oncology Case Consults

The Patient with Chronic Lymphocytic Leukemia

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with chronic lymphocytic leukemia.
More »
Meeting News Coverage Video
VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

VIDEO: PALOMA-3 trial represents 'enormous gain' for patients with hormone-positive breast cancer

August 20, 2015
CHICAGO — The PALOMA-3 trial, which evaluated the addition of palbociclib to fulvestrant, demonstrated…
More »
CME
Updates in Immunotherapy – Philadelphia 2015

Updates in Immunotherapy – Philadelphia 2015

This activity is supported by an educational grant from Merck & Co., Inc.

The promise of immunotherapy in oncology has become a reality with the US Food and Drug Administration (FDA) approval…
More »